Skip to content
    CRNX
    Earnings call· Dec 2025(Q4 FY25)

    Crinetics Pharmaceuticals Q4 FY25 earnings call CRNX

    Feb 26, 2026 Source

    Executive summary

    Crinetics Pharmaceuticals Q4 FY25 — PALSONIFY Launch Progress and Pipeline Advancement

    Crinetics Pharmaceuticals reported a strong Q4 FY25, marked by the successful commercial launch of PALSONIFY for acromegaly, demonstrating early prescriber uptake and favorable payer access. The company also advanced its late-stage pipeline with atumelnant studies in CAH and Cushing's disease, and initiated a Phase I/II study for CRN09682. With a robust cash position, the focus is on building a sustainable endocrinology business and expanding its innovative therapeutic portfolio.

    Highlights

    5
    • Successfully launched PALSONIFY with over 200 enrollment forms in Q4 FY25.

    • Achieved engagement with more than 125 unique prescribers for PALSONIFY in community and pituitary treatment centers.

    • Secured early and encouraging formulary momentum for PALSONIFY, including wins with top plans.

    • Ended 2025 with over $1 billion in cash, cash equivalents, and investments, supplemented by an additional $380 million from a January 2026 public offering.

    • Received a positive CHMP opinion for PALSONIFY in acromegaly, reflecting strong data and potential benefit in the EU.

    Concerns

    2
    • Lumpy PALSONIFY Launch Cadence

    • Acute Adrenal Insufficiency Risk with Atumelnant

    Guidance & targets

    3
    CategoryTargetConfidence
    GAAP operating expenses
    $600 million to $650 million
    high materiality
    High
    Non-GAAP operating expenses
    $480 million to $520 million
    high materiality
    High
    Cash runway
    into 2030
    high materiality
    High

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    Acromegaly (PALSONIFY)
    PALSONIFY is the first commercial product, launched in Q4 FY25. Early uptake is strong with significant prescriber engagement and encouraging formulary momentum. The company aims for PALSONIFY to become the new standard of care for acromegaly.
    Net product revenue: $5.4 millionEnrollment forms in Q4 FY25: >200Unique prescribers: >125Initial claims reimbursed: 50%Initial claims on Quickstart: 50%
    $5.4 million

    Operational metrics

    18
    Total net revenue
    $6.2 million
    Q4 FY25

    Consisting of $5.4 million in net product revenue from PALSONIFY and $0.8 million from licensing agreement.

    Total net revenue
    $7.7 million
    FY25
    Net product revenue
    $5.4 million
    Q4 FY25
    Licensing revenue
    $0.8 million
    Q4 FY25
    Cost of product revenue
    $1.1 million
    Q4 FY25

    Prior to PALSONIFY's approval, manufacturing costs were expensed through R&D as zero-cost inventory. The cost relates to commercial manufacturing capacity expansion and distribution/fulfillment.

    R&D expenses
    $85.1 milliondown from $90.5 million in Q3 FY25
    Q4 FY25

    Decrease is a result of start-up costs for ongoing clinical studies recognized during the third quarter.

    SG&A expenses
    $53.7 millionsteady compared to $52.3 million in Q3 FY25
    Q4 FY25

    Field force, commercial team, and corporate functions were already in place prior to approval.

    Net cash used
    $326.2 millionfavorable relative to $340 million to $370 million guidance
    FY25

    Primarily due to working capital timing and a modest increase in cash flows from employee option proceeds during the fourth quarter.

    Cash, cash equivalents and investments
    >$1 billion
    end of FY25

    Does not include net proceeds from January 2026 public offering.

    Net proceeds from public offering
    $380 million
    January 2026

    Public offering completed in January 2026.

    Total cash, cash equivalents and investments
    ~$1.4 billion
    immediately after January 2026 offering

    Includes the net proceeds from the January 2026 public offering.

    Common stock outstanding
    104.7 million
    as of 2026-02-13
    Fully diluted shares outstanding
    121 million
    as of 2026-02-13

    Includes outstanding options, unvested restricted stock units, and shares expected to be purchased under employee stock purchase plan.

    PALSONIFY enrollment forms
    >200
    Q4 FY25

    Included all 22 U.S. participants in the open-label extension studies of the clinical program.

    PALSONIFY unique prescribers
    >125
    Q4 FY25

    In both community and pituitary treatment center practices.

    PALSONIFY initial claims reimbursed
    50%
    initial point of measurement

    For commercial or Medicare and Medicaid.

    PALSONIFY initial claims on Quickstart
    50%
    initial point of measurement
    PALSONIFY Quickstart program duration
    18 months
    expected

    Expected to be less prominent over time as direct access in formularies increases.

    Industry KPIs

    1
    MetricValueDetails
    EPS revenue guidanceGAAP operating expenses $600M-$650M; Non-GAAP operating expenses $480M-$520MUSD

    Deals & partnerships

    1
    SKKLicensing agreement for PALSONIFY in Japan$0.8 million

    Revenue from licensing agreement with Japanese partner.

    Risks & headwinds

    2
    Lumpy PALSONIFY Launch CadenceNear-term

    lumpy

    Mitigation: Continued execution by the commercial team, increasing field interactions, and expanding market access.

    Acute Adrenal Insufficiency Risk with AtumelnantDuring treatment with atumelnant

    potentially dangerous episodes

    Mitigation: Proactive 'block and replace' approach with low-dose glucocorticoid replacement initiated early in the EQUILIBRIUM ADCS study.

    What to watch in Q1 FY26

    5

    PALSONIFY Enrollment Forms

    Next quarter
    Current>200 forms in Q4 FY25
    TargetContinued growth/stabilization of enrollment forms

    Why it matters

    Indicates early commercial traction and prescriber adoption for the newly launched product, crucial for market penetration.

    In Q4, we received more than 200 enrollment forms.

    Q&A highlights

    5

    How did previous Cushing's data, specifically from Lancet GRACE or relacorilant CRL, inform the design of the EQUILIBRIUM study, particularly regarding clinically meaningful endpoints?

    Alan Krasner explained that the primary endpoint of normalization of urine-free cortisol is well-precedented for drugs that allow direct cortisol measurement. He differentiated atumelnant from glucocorticoid receptor antagonists like relacorilant, where cortisol cannot be used as a marker, and emphasized that atumelnant allows measurement of both cortisol and clinical outcome benefits.

    The primary endpoint, for example, is known to be normalization of urine-free cortisol for drugs in which you can measure cortisol as the biochemical marker for Cushing's disease activity.

    asked by Maxwell Skor · answered by Alan Krasner

    2 min read5 chapters

    Detailed Narrative

    01

    PALSONIFY Commercialization Strategy and Early Success

    Crinetics has successfully launched PALSONIFY, its first commercial product for acromegaly, building a fully integrated commercial enterprise. The company's strategy emphasizes efficacy-first messaging, highlighting fast onset of action and symptom control, which is resonating with healthcare providers and patients. The commercial team includes sales professionals, nurse educators, field reimbursement specialists, and patient ambassadors to support patient access and education. The goal is to establish PALSONIFY as the new standard of care for acromegaly and leverage this commercial infrastructure for future pipeline launches.

    02

    Atumelnant Development for ACTH-Dependent Cushing's Syndrome (ADCS)

    Atumelnant, an ACTH receptor antagonist, is being advanced for ACTH-dependent Cushing's Syndrome (ADCS), a rare and challenging disease. Initial Phase Ib/IIa data from an NIH collaboration demonstrated rapid and significant reductions in 24-hour urine-free cortisol (UFC) within days, with atumelnant generally well tolerated. The upcoming EQUILIBRIUM ADCS study, a seamless Phase II/III trial, will evaluate a dose range of 20mg to 80mg, exploring both reactive and proactive glucocorticoid replacement strategies to prevent adrenal insufficiency. The study aims to identify the optimal dose and replacement paradigm for the confirmatory Phase III.

    03

    CRN09682 Non-Peptide Drug Conjugate Program

    The company's novel non-peptide drug conjugate program has advanced its first candidate, CRN09682, into the dose escalation phase of a Phase I/II basket study for SST2-expressing tumors. This program aims to utilize small molecule targeting for various payloads, offering potential benefits over antibody or peptide targeting. Patient selection for the BRAVESST trial requires documented SST2 receptor expression and progressive disease. The study will explore activity in a broad range of tumors, including neuroendocrine tumors, meningiomas, HR-positive breast tumors, and head and neck tumors, with safety and toleration as primary endpoints for Phase I.

    04

    Pipeline Expansion and Long-Term Business Building

    Crinetics is strategically transitioning from a pipeline-focused company to a sustainable commercial business. The successful launch of PALSONIFY provides a foundation for future product introductions. The company plans to leverage its commercial capabilities to launch paltusotine for carcinoid syndrome, atumelnant for CAH and Cushing's, and other pipeline candidates. This integrated approach, focusing on endocrinology, aims to create significant long-term value and establish Crinetics as a leading endocrinology company.

    05

    Payer Dynamics and Access for PALSONIFY

    Payer access for PALSONIFY is progressing favorably, with most coverage aligning with the product's label and prior authorizations proceeding smoothly. Approximately 50% of initial claims are being reimbursed directly by commercial, Medicare, or Medicaid plans, while the remaining 50% utilize a Quickstart program. The company anticipates that the Quickstart program will become less prominent over the next 18 months as direct formulary access increases, ensuring broader and more streamlined patient access to PALSONIFY.

    AI-generated summary of the company’s earnings call. Not investment advice.